Current practices and guidelines for clinical next-generation sequencing oncology testing

Samuel P Strom

doi:10.28092/j.issn.2095-3941.2016.0004

Current practices and guidelines for clinical next-generation sequencing oncology testing

Cancer Biol Med. 2016 Mar;13(1):3-11. doi: 10.28092/j.issn.2095-3941.2016.0004.

Author

Samuel P Strom¹

Affiliation

¹ Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.

PMID: 27144058
PMCID: PMC4850126
DOI: 10.28092/j.issn.2095-3941.2016.0004

Abstract

Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadth genomic of information available to oncologists and their patients. This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.

Keywords: Cancer genomics; molecular diagnostics; next-generation sequencing.